Welcome to our dedicated page for Cytosorbents news (Ticker: CTSO), a resource for investors and traders seeking the latest updates and insights on Cytosorbents stock.
CytoSorbents Corporation (NASDAQ: CTSO) generates frequent news flow around its blood purification technologies for intensive care and cardiac surgery. Company updates often center on clinical data, regulatory milestones, and commercial progress for its lead product CytoSorb® and its investigational DrugSorb™-ATR antithrombotic removal system.
Investors following CTSO news can expect announcements on quarterly and annual financial results, including revenue trends, gross margins, and cash flow initiatives, as seen in recent preliminary and reported results. Regulatory developments are another major theme, with detailed disclosures on the De Novo pathway for DrugSorb‑ATR, FDA appeal outcomes, pre‑submission meetings, and anticipated review timelines, as well as interactions with Health Canada.
CytoSorbents also issues news on scientific and medical events, such as presentations at major healthcare and cardiothoracic surgery conferences, company‑sponsored symposia, and global webinars on topics like sepsis and septic shock. These releases highlight new randomized trial results, real‑world evidence, and meta‑analyses involving CytoSorb and DrugSorb‑ATR, along with educational efforts aimed at clinicians in critical care and cardiac surgery.
Additional coverage includes participation in investor conferences, amendments to credit agreements, and workforce and cost reduction programs intended to influence the company’s financial trajectory. For readers tracking CTSO stock, the news stream provides insight into how CytoSorbents is advancing its blood purification platform, pursuing regulatory approvals, and expanding clinical adoption across high‑risk ICU and surgical indications. Bookmark this page to review the latest press releases, event notices, and business updates related to CytoSorbents.
CytoSorbents Corporation (Nasdaq: CTSO) announced the pricing of a public offering of 5,263,158 shares at $9.50 per share, generating gross proceeds of approximately $50 million. The offering's closure is expected on July 24, 2020, pending customary conditions. The funds will be used for general corporate purposes, including expansion in manufacturing, research and development, and clinical studies. The underwriters also have a 30-day option to purchase an additional 789,473 shares. Cowen and SVB Leerink are the joint book-running managers for this offering.
CytoSorbents Corporation (NASDAQ: CTSO) reported preliminary financial results for Q2 2020 with a total revenue of approximately $9.8 million, marking a 58% increase from $6.2 million in Q2 2019. Product revenues reached $9.5 million, up 61% year-over-year and 16% sequentially. The company generated about $667,000 in U.S. hospital sales for COVID-19 patients. Cash balance stood at $35.1 million. CytoSorb has now been used in over 98,000 treatments worldwide.
CytoSorbents Corporation (Nasdaq: CTSO) has announced a proposed public offering of $40 million in common stock. The offering may include a 30-day option for underwriters to purchase an additional 15% of the shares sold. Proceeds will be allocated for general corporate purposes, including expanding manufacturing, R&D, and clinical studies, as well as supporting sales and marketing efforts. The offering is subject to market conditions, and the company cautions that actual completion and size may differ.
Summary not available.
CytoSorbents Corporation (NASDAQ:CTSO) announced a Key Opinion Leader call scheduled for July 13, 2020, at 11:00 AM EDT, focusing on the use of CytoSorb technology to safely remove antithrombotic medications from patients at risk of bleeding during surgery. Notable speakers include Dr. Michael Gibson from Harvard University, Dr. Robert Storey from the University of Sheffield, and Prof. Michael Schmoeckel from Hamburg, Germany. The discussion will address the importance of managing patients on blood thinners to prevent life-threatening perioperative bleeding.
CytoSorbents Corporation (NASDAQ: CTSO) has announced the commercial launch of its CytoSorb blood purification technology in nine Latin American countries, including Colombia, Argentina, and Peru, amidst rising COVID-19 cases. The product helps treat dangerous inflammation in critically-ill patients and is now available in 65 countries globally. The launch is timely; Latin America reports over 2.1 million COVID-19 cases and a mortality rate of 4.6%. With the ongoing pandemic, CytoSorb is expected to play a crucial role in addressing cytokine storm complications in COVID-19 patients.